1	Lactate-dehydrogenase	_	NN	_	_	3	VMOD	_	_
2	5	_	CD	_	_	1	NMOD	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	overexpressed	_	VBN	_	_	3	VC	_	_
5	in	_	IN	_	_	4	VMOD	_	_
6	non-small	_	JJ	_	_	9	NMOD	_	_
7	cell	_	NN	_	_	9	NMOD	_	_
8	lung	_	NN	_	_	9	NMOD	_	_
9	cancer	_	NN	_	_	5	PMOD	_	_
10	and	_	CC	_	_	3	COORD	_	_
11	correlates	_	VBZ	_	_	10	CONJ	_	_
12	with	_	IN	_	_	11	VMOD	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	expression	_	NN	_	_	12	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	the	_	DT	_	_	18	NMOD	_	_
17	transketolase-like	_	JJ	_	_	18	NMOD	_	_
18	protein	_	NN	_	_	15	PMOD	_	_
19	1	_	CD	_	_	18	NMOD	_	_
20	.	_	.	_	_	3	P	_	_
		
1	AIMS	_	NNS	_	_	0	ROOT	_	_
2	:	_	:	_	_	1	P	_	_
3	As	_	IN	_	_	16	VMOD	_	_
4	one	_	CD	_	_	3	PMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	13	NMOD	_	_
7	five	_	CD	_	_	13	NMOD	_	_
8	lactate	_	NN	_	_	9	NMOD	_	_
9	dehydrogenase	_	NN	_	_	13	NMOD	_	_
10	(	_	(	_	_	11	P	_	_
11	LDH	_	NN	_	_	9	PRN	_	_
12	)	_	)	_	_	11	P	_	_
13	isoenzymes	_	NNS	_	_	5	PMOD	_	_
14	,	_	,	_	_	16	P	_	_
15	LDH5	_	NN	_	_	16	VMOD	_	_
16	has	_	VBZ	_	_	1	NMOD	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	highest	_	JJS	_	_	19	NMOD	_	_
19	efficiency	_	NN	_	_	16	VMOD	_	_
20	to	_	TO	_	_	19	NMOD	_	_
21	catalyze	_	VB	_	_	20	IM	_	_
22	pyruvate	_	NN	_	_	23	NMOD	_	_
23	transformation	_	NN	_	_	21	VMOD	_	_
24	to	_	TO	_	_	23	NMOD	_	_
25	lactate	_	NN	_	_	24	PMOD	_	_
26	.	_	.	_	_	1	P	_	_
		
1	LDH5	_	NN	_	_	2	NMOD	_	_
2	overexpression	_	NN	_	_	6	VMOD	_	_
3	in	_	IN	_	_	2	NMOD	_	_
4	cancer	_	NN	_	_	5	NMOD	_	_
5	cells	_	NNS	_	_	3	PMOD	_	_
6	induces	_	VBZ	_	_	0	ROOT	_	_
7	an	_	DT	_	_	10	NMOD	_	_
8	upregulated	_	VBN	_	_	10	NMOD	_	_
9	glycolytic	_	JJ	_	_	10	NMOD	_	_
10	metabolism	_	NN	_	_	6	VMOD	_	_
11	and	_	CC	_	_	10	COORD	_	_
12	reduced	_	VBN	_	_	13	NMOD	_	_
13	dependence	_	NN	_	_	11	CONJ	_	_
14	on	_	IN	_	_	13	NMOD	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	presence	_	NN	_	_	14	PMOD	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	oxygen	_	NN	_	_	17	PMOD	_	_
19	.	_	.	_	_	6	P	_	_
		
1	Here	_	RB	_	_	3	VMOD	_	_
2	we	_	PRP	_	_	3	VMOD	_	_
3	analyzed	_	VBD	_	_	0	ROOT	_	_
4	LDH5	_	NN	_	_	6	NMOD	_	_
5	protein	_	NN	_	_	6	NMOD	_	_
6	expression	_	NN	_	_	3	VMOD	_	_
7	in	_	IN	_	_	6	NMOD	_	_
8	a	_	DT	_	_	12	NMOD	_	_
9	well	_	RB	_	_	10	AMOD	_	_
10	characterized	_	VBN	_	_	12	NMOD	_	_
11	large	_	JJ	_	_	12	NMOD	_	_
12	cohort	_	NN	_	_	7	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	primary	_	JJ	_	_	16	NMOD	_	_
15	lung	_	NN	_	_	16	NMOD	_	_
16	cancers	_	NNS	_	_	13	PMOD	_	_
17	in	_	IN	_	_	16	NMOD	_	_
18	correlation	_	NN	_	_	17	PMOD	_	_
19	to	_	TO	_	_	18	NMOD	_	_
20	clinico-pathological	_	JJ	_	_	21	NMOD	_	_
21	data	_	NNS	_	_	19	PMOD	_	_
22	and	_	CC	_	_	18	COORD	_	_
23	its	_	PRP$	_	_	25	NMOD	_	_
24	possible	_	JJ	_	_	25	NMOD	_	_
25	impact	_	NN	_	_	22	CONJ	_	_
26	on	_	IN	_	_	25	NMOD	_	_
27	patient	_	NN	_	_	28	NMOD	_	_
28	survival	_	NN	_	_	26	PMOD	_	_
29	.	_	.	_	_	3	P	_	_
		
1	METHODS	_	NNS	_	_	0	ROOT	_	_
2	:	_	:	_	_	1	P	_	_
3	Primary	_	JJ	_	_	5	NMOD	_	_
4	lung	_	NN	_	_	5	NMOD	_	_
5	cancers	_	NNS	_	_	21	VMOD	_	_
6	(	_	(	_	_	7	P	_	_
7	n	_	NN	_	_	5	PRN	_	_
8	=	_	JJ	_	_	7	NMOD	_	_
9	269	_	CD	_	_	7	NMOD	_	_
10	)	_	)	_	_	7	P	_	_
11	and	_	CC	_	_	5	COORD	_	_
12	non	_	JJ	_	_	15	NMOD	_	_
13	neoplastic	_	JJ	_	_	15	NMOD	_	_
14	lung	_	NN	_	_	15	NMOD	_	_
15	tissue	_	NN	_	_	11	CONJ	_	_
16	(	_	(	_	_	17	P	_	_
17	n	_	NN	_	_	15	PRN	_	_
18	=	_	JJ	_	_	17	NMOD	_	_
19	35	_	CD	_	_	17	NMOD	_	_
20	)	_	)	_	_	17	P	_	_
21	were	_	VBD	_	_	1	NMOD	_	_
22	tested	_	VBN	_	_	21	VC	_	_
23	for	_	IN	_	_	22	VMOD	_	_
24	LDH5	_	NN	_	_	25	NMOD	_	_
25	expression	_	NN	_	_	23	PMOD	_	_
26	by	_	IN	_	_	22	VMOD	_	_
27	immunohistochemistry	_	NN	_	_	26	PMOD	_	_
28	using	_	VBG	_	_	27	APPO	_	_
29	a	_	DT	_	_	32	NMOD	_	_
30	polyclonal	_	JJ	_	_	32	NMOD	_	_
31	LDH5	_	NN	_	_	32	NMOD	_	_
32	antibody	_	NN	_	_	28	VMOD	_	_
33	(	_	(	_	_	34	P	_	_
34	ab53010	_	NN	_	_	32	PRN	_	_
35	)	_	)	_	_	34	P	_	_
36	.	_	.	_	_	1	P	_	_
		
1	The	_	DT	_	_	2	NMOD	_	_
2	results	_	NNS	_	_	6	VMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	LDH5	_	NN	_	_	5	NMOD	_	_
5	expression	_	NN	_	_	3	PMOD	_	_
6	were	_	VBD	_	_	0	ROOT	_	_
7	correlated	_	VBN	_	_	6	VC	_	_
8	to	_	TO	_	_	7	VMOD	_	_
9	clinico-pathological	_	JJ	_	_	10	NMOD	_	_
10	data	_	NNS	_	_	8	PMOD	_	_
11	as	_	RB	_	_	8	COORD	_	_
12	well	_	RB	_	_	11	DEP	_	_
13	as	_	IN	_	_	11	DEP	_	_
14	to	_	TO	_	_	11	CONJ	_	_
15	patient	_	NN	_	_	17	NMOD	_	_
16	's	_	POS	_	_	17	SUFFIX	_	_
17	survival	_	NN	_	_	14	PMOD	_	_
18	.	_	.	_	_	6	P	_	_
		
1	In	_	IN	_	_	18	VMOD	_	_
2	addition	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	18	P	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	results	_	NNS	_	_	18	VMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	the	_	DT	_	_	10	NMOD	_	_
8	previously	_	RB	_	_	9	AMOD	_	_
9	tested	_	VBN	_	_	10	NMOD	_	_
10	transketolase	_	NN	_	_	6	PMOD	_	_
11	like	_	IN	_	_	10	NMOD	_	_
12	1	_	CD	_	_	17	NMOD	_	_
13	protein	_	NN	_	_	17	NMOD	_	_
14	(	_	(	_	_	17	P	_	_
15	TKTL1	_	NN	_	_	17	NMOD	_	_
16	)	_	)	_	_	17	P	_	_
17	expression	_	NN	_	_	11	PMOD	_	_
18	were	_	VBD	_	_	0	ROOT	_	_
19	correlated	_	VBN	_	_	18	VC	_	_
20	to	_	TO	_	_	19	VMOD	_	_
21	LDH5	_	NN	_	_	22	NMOD	_	_
22	expression	_	NN	_	_	20	PMOD	_	_
23	.	_	.	_	_	18	P	_	_
		
1	RESULTS	_	NNS	_	_	0	ROOT	_	_
2	:	_	:	_	_	1	P	_	_
3	89.5	_	CD	_	_	4	NMOD	_	_
4	%	_	NN	_	_	12	VMOD	_	_
5	(	_	(	_	_	6	P	_	_
6	n	_	NN	_	_	4	PRN	_	_
7	=	_	JJ	_	_	6	NMOD	_	_
8	238	_	CD	_	_	6	NMOD	_	_
9	)	_	)	_	_	6	P	_	_
10	of	_	IN	_	_	4	NMOD	_	_
11	NSCLC	_	NN	_	_	10	PMOD	_	_
12	revealed	_	VBD	_	_	1	NMOD	_	_
13	LDH5	_	NN	_	_	14	NMOD	_	_
14	expression	_	NN	_	_	12	VMOD	_	_
15	whereas	_	IN	_	_	12	VMOD	_	_
16	LDH5	_	NN	_	_	17	NMOD	_	_
17	expression	_	NN	_	_	18	VMOD	_	_
18	was	_	VBD	_	_	15	SUB	_	_
19	not	_	RB	_	_	18	VMOD	_	_
20	detected	_	VBN	_	_	18	VC	_	_
21	in	_	IN	_	_	20	VMOD	_	_
22	non	_	JJ	_	_	25	NMOD	_	_
23	neoplastic	_	JJ	_	_	25	NMOD	_	_
24	lung	_	NN	_	_	25	NMOD	_	_
25	tissues	_	NNS	_	_	21	PMOD	_	_
26	(	_	(	_	_	27	P	_	_
27	n	_	NN	_	_	25	PRN	_	_
28	=	_	JJ	_	_	27	NMOD	_	_
29	34	_	CD	_	_	27	NMOD	_	_
30	)	_	)	_	_	27	P	_	_
31	(	_	(	_	_	33	P	_	_
32	p	_	NN	_	_	33	NMOD	_	_
33	<	_	NN	_	_	25	PRN	_	_
34	0.0001	_	CD	_	_	33	NMOD	_	_
35	)	_	)	_	_	33	P	_	_
36	.	_	.	_	_	1	P	_	_
		
1	LDH5	_	NN	_	_	2	NMOD	_	_
2	overexpression	_	NN	_	_	3	VMOD	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	associated	_	VBN	_	_	3	VC	_	_
5	with	_	IN	_	_	4	VMOD	_	_
6	histological	_	JJ	_	_	7	NMOD	_	_
7	type	_	NN	_	_	5	PMOD	_	_
8	(	_	(	_	_	29	P	_	_
9	adenocarcinoma	_	NN	_	_	12	NMOD	_	_
10	=	_	JJ	_	_	12	NMOD	_	_
11	57	_	CD	_	_	12	NMOD	_	_
12	%	_	NN	_	_	29	DEP	_	_
13	,	_	,	_	_	29	P	_	_
14	squamous	_	JJ	_	_	16	NMOD	_	_
15	cell	_	NN	_	_	16	NMOD	_	_
16	carcinoma	_	NN	_	_	29	DEP	_	_
17	=	_	JJ	_	_	16	APPO	_	_
18	45	_	CD	_	_	19	NMOD	_	_
19	%	_	NN	_	_	17	AMOD	_	_
20	,	_	,	_	_	29	P	_	_
21	large	_	JJ	_	_	23	NMOD	_	_
22	cell	_	NN	_	_	23	NMOD	_	_
23	carcinoma	_	NN	_	_	29	DEP	_	_
24	=	_	JJ	_	_	23	APPO	_	_
25	46	_	CD	_	_	26	NMOD	_	_
26	%	_	NN	_	_	24	AMOD	_	_
27	,	_	,	_	_	29	P	_	_
28	p	_	NN	_	_	29	VMOD	_	_
29	=	_	JJ	_	_	7	PRN	_	_
30	0.006	_	CD	_	_	29	VMOD	_	_
31	)	_	)	_	_	29	P	_	_
32	.	_	.	_	_	3	P	_	_
		
1	No	_	DT	_	_	3	NMOD	_	_
2	significant	_	JJ	_	_	3	NMOD	_	_
3	correlation	_	NN	_	_	4	VMOD	_	_
4	could	_	MD	_	_	0	ROOT	_	_
5	be	_	VB	_	_	4	VC	_	_
6	detected	_	VBN	_	_	5	VC	_	_
7	with	_	IN	_	_	6	VMOD	_	_
8	regard	_	NN	_	_	7	PMOD	_	_
9	to	_	TO	_	_	8	NMOD	_	_
10	TNM-stage	_	NN	_	_	9	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	grading	_	NN	_	_	10	COORD	_	_
13	or	_	CC	_	_	12	COORD	_	_
14	survival	_	NN	_	_	13	CONJ	_	_
15	.	_	.	_	_	4	P	_	_
		
1	A	_	DT	_	_	4	NMOD	_	_
2	two	_	CD	_	_	4	NMOD	_	_
3	sided	_	JJ	_	_	4	NMOD	_	_
4	correlation	_	NN	_	_	12	VMOD	_	_
5	between	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	7	NMOD	_	_
7	expression	_	NN	_	_	5	PMOD	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	TKTL1	_	NN	_	_	8	PMOD	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	LDH5	_	NN	_	_	10	CONJ	_	_
12	could	_	MD	_	_	0	ROOT	_	_
13	be	_	VB	_	_	12	VC	_	_
14	shown	_	VBN	_	_	13	VC	_	_
15	(	_	(	_	_	17	P	_	_
16	p	_	NN	_	_	17	VMOD	_	_
17	=	_	JJ	_	_	14	PRN	_	_
18	0.002	_	CD	_	_	17	VMOD	_	_
19	)	_	)	_	_	17	P	_	_
20	within	_	IN	_	_	14	VMOD	_	_
21	the	_	DT	_	_	23	NMOD	_	_
22	overall	_	JJ	_	_	23	NMOD	_	_
23	cohort	_	NN	_	_	20	PMOD	_	_
24	as	_	RB	_	_	20	COORD	_	_
25	well	_	RB	_	_	24	DEP	_	_
26	as	_	IN	_	_	24	DEP	_	_
27	for	_	IN	_	_	24	CONJ	_	_
28	each	_	DT	_	_	32	NMOD	_	_
29	grading	_	NN	_	_	32	NMOD	_	_
30	and	_	CC	_	_	29	COORD	_	_
31	pN	_	NN	_	_	30	CONJ	_	_
32	group	_	NN	_	_	27	PMOD	_	_
33	.	_	.	_	_	12	P	_	_
		
1	A	_	DT	_	_	3	NMOD	_	_
2	significant	_	JJ	_	_	3	NMOD	_	_
3	correlation	_	NN	_	_	12	VMOD	_	_
4	between	_	IN	_	_	3	NMOD	_	_
5	LDH5	_	NN	_	_	4	PMOD	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	TKTL1	_	NN	_	_	6	CONJ	_	_
8	within	_	IN	_	_	3	NMOD	_	_
9	each	_	DT	_	_	11	NMOD	_	_
10	histologic	_	JJ	_	_	11	NMOD	_	_
11	tumortype	_	NN	_	_	8	PMOD	_	_
12	could	_	MD	_	_	0	ROOT	_	_
13	not	_	RB	_	_	12	VMOD	_	_
14	be	_	VB	_	_	12	VC	_	_
15	revealed	_	VBN	_	_	14	VC	_	_
16	.	_	.	_	_	12	P	_	_
		
1	CONCLUSIONS	_	NNS	_	_	0	ROOT	_	_
2	:	_	:	_	_	1	P	_	_
3	LDH5	_	NN	_	_	4	VMOD	_	_
4	is	_	VBZ	_	_	1	NMOD	_	_
5	overexpressed	_	VBN	_	_	4	VC	_	_
6	in	_	IN	_	_	5	VMOD	_	_
7	NSCLC	_	NN	_	_	6	PMOD	_	_
8	and	_	CC	_	_	4	COORD	_	_
9	could	_	MD	_	_	8	CONJ	_	_
10	hence	_	RB	_	_	9	VMOD	_	_
11	serve	_	VB	_	_	9	VC	_	_
12	as	_	IN	_	_	11	VMOD	_	_
13	an	_	DT	_	_	15	NMOD	_	_
14	additional	_	JJ	_	_	15	NMOD	_	_
15	marker	_	NN	_	_	12	PMOD	_	_
16	for	_	IN	_	_	15	NMOD	_	_
17	malignancy	_	NN	_	_	16	PMOD	_	_
18	.	_	.	_	_	1	P	_	_
		
1	Furthermore	_	RB	_	_	4	VMOD	_	_
2	,	_	,	_	_	4	P	_	_
3	LDH5	_	NN	_	_	4	VMOD	_	_
4	correlates	_	VBZ	_	_	0	ROOT	_	_
5	positively	_	RB	_	_	4	VMOD	_	_
6	with	_	IN	_	_	4	VMOD	_	_
7	the	_	DT	_	_	10	NMOD	_	_
8	prognostic	_	JJ	_	_	10	NMOD	_	_
9	marker	_	NN	_	_	10	NMOD	_	_
10	TKTL1	_	NN	_	_	6	PMOD	_	_
11	.	_	.	_	_	4	P	_	_
		
1	Our	_	PRP$	_	_	2	NMOD	_	_
2	results	_	NNS	_	_	3	VMOD	_	_
3	confirm	_	VBP	_	_	0	ROOT	_	_
4	a	_	DT	_	_	6	NMOD	_	_
5	close	_	JJ	_	_	6	NMOD	_	_
6	link	_	NN	_	_	3	VMOD	_	_
7	between	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	11	NMOD	_	_
9	two	_	CD	_	_	11	NMOD	_	_
10	metabolic	_	JJ	_	_	11	NMOD	_	_
11	enzymes	_	NNS	_	_	7	PMOD	_	_
12	and	_	CC	_	_	3	COORD	_	_
13	indicate	_	VBP	_	_	12	CONJ	_	_
14	an	_	DT	_	_	15	NMOD	_	_
15	alteration	_	NN	_	_	13	VMOD	_	_
16	in	_	IN	_	_	15	NMOD	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	glucose	_	NN	_	_	19	NMOD	_	_
19	metabolism	_	NN	_	_	16	PMOD	_	_
20	in	_	IN	_	_	19	NMOD	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	process	_	NN	_	_	20	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	malignant	_	JJ	_	_	25	NMOD	_	_
25	transformation	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	3	P	_	_
		
